Nerve Tape: Smithfield BioScience, BioCircuit Technologies to Deliver Innovative Nerve Repair Solution

Nerve Tape® will allow for suture-less surgical repair following traumatic injuries  

BioCircuit Technologies, a National Institutes of Health (NIH)-funded medical device company focused on tissue repair and neural interfacing, and Smithfield BioScience, a unit of Smithfield Foods delivering life-saving medical solutions from porcine-derived bioproducts, today announced the companies will produce Nerve Tape®, a medical device enabling suture-less nerve repair following traumatic injuries. The technology will allow surgeons to operate faster and achieve precise, reliable rejoining of injured nerves, simplifying the surgical process and improving patient outcomes.

Nerve Tape is an implantable device composed of decellularized porcine small intestinal submucosa (SIS) embedded with microscale hooks for tissue attachment. It can be quickly and easily wrapped around two ends of a severed nerve to form a strong, reliable connection with distributed tension to promote regeneration. The devices will be prepared from fully traceable SIS tissue harvested from Smithfield’s U.S. operations.

“Our work with BioCircuit demonstrates our expanding portfolio and the value we are creating in a variety of markets through Smithfield’s vertically integrated supply chain and manufacturing expertise,” said Courtney Stanton, President of Smithfield BioScience. “By harvesting porcine bioproducts for medical applications – such as organs, mucosa, and tissues – we have the ability to improve lives through the development of innovative pharmaceuticals and medical devices like this one.”

“We look forward to working with Smithfield BioScience to bring this promising medical device solution to life,” said Michelle Jarrard, CEO of BioCircuit Technologies. “BioCircuit is committed to developing medical technologies, such as Nerve Tape®, to repair, monitor, and control peripheral nerves precisely and reliably. We’re excited to tap into Smithfield’s exceptional level of traceability and product safety in our work to empower surgeons with powerful, practical clinical tools that improve the treatment of injuries.”

In parallel with establishing a commercial supply chain for Nerve Tape®, BioCircuit is also developing non-invasive, bioelectronic devices able to tap into nerve and muscle activity to provide sensitive, high-resolution monitoring and selective, closed-loop stimulation. Useful in the fields of bioelectronic medicine, neuromodulation, neuro-prosthetics, and neuromuscular rehabilitation, this bioelectronics technology provides clinicians with the ability to diagnose health conditions earlier, precisely deliver therapies, and track outcomes over time.

Smithfield BioScience leverages Smithfield’s vertically integrated platform to supply the pharmaceutical and medical device industries with a secure source of porcine-derived products fully traceable to their farms of origin. Since its inception in 2017, Smithfield BioScience has become a leading U.S. manufacturer of heparin, an essential pharmaceutical product used to prevent the formation of blood clots during certain medical procedures or in patients at risk for clots.

About Smithfield Foods, Inc.
Headquartered in Smithfield, Va. since 1936, Smithfield Foods, Inc. is an American food company with agricultural roots and a global reach. With more than 60,000 jobs globally, we are dedicated to producing “Good food. Responsibly®” and serve as one of the world’s leading vertically integrated protein companies. We have pioneered sustainability standards for more than two decades, including our industry-leading commitments to become carbon negative in our U.S. company-owned operations and reduce GHG emissions 30 percent across our entire U.S. value chain by 2030.

About BioCircuit Technologies 
Based in Atlanta, GA, BioCircuit Technologies develops and commercializes medical devices for tissue repair and neural interfacing. Designed for ease-of-use and reliability, these devices enhance therapeutic targeting, diagnostic precision, and surgical consistency for improved patient outcomes.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy